BioNTech (BNTX) PT Lowered to $110 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts BNTX Hot Sheet
Price: $96.44 -0.47%
Rating Summary:
16 Buy, 7 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 25
Rating Summary:
16 Buy, 7 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 25
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison lowered the price target on BioNTech (NASDAQ: BNTX) to $110.00 (from $116.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Enovis Corp (ENOV) PT Lowered to $44 at UBS
- CME Group (CME) PT Raised to $300 at TD Cowen on 'Broadening Growth Drivers'
- Integra LifeSciences (IART) PT Lowered to $15 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
